Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Income (2016 - 2025)

Historic Net Income for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2024 value amounting to $139.8 million.

  • Seres Therapeutics' Net Income rose 214431.93% to $139.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $139.8 million, marking a year-over-year increase of 61261.64%. This contributed to the annual value of $125.9 million for FY2024, which is 6478.68% up from last year.
  • Latest data reveals that Seres Therapeutics reported Net Income of $139.8 million as of Q3 2024, which was up 214431.93% from -$6.7 million recorded in Q2 2024.
  • Over the past 5 years, Seres Therapeutics' Net Income peaked at $139.8 million during Q3 2024, and registered a low of -$71.5 million during Q1 2023.
  • Over the past 5 years, Seres Therapeutics' median Net Income value was -$20.2 million (recorded in 2020), while the average stood at -$13.1 million.
  • As far as peak fluctuations go, Seres Therapeutics' Net Income tumbled by 19726.9% in 2023, and later surged by 214431.93% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Net Income stood at -$18.0 million in 2020, then crashed by 175.35% to -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 197.27% to -$6.5 million in 2023, then soared by 2240.73% to $139.8 million in 2024.
  • Its Net Income was $139.8 million in Q3 2024, compared to -$6.7 million in Q2 2024 and -$7.2 million in Q1 2024.